

Applicant : Takuya Tamatani et al.
Serial No. : 09/383,551
Filed : August 26, 1999
Page : 2

Attorney's Docket No. 06501-039001 / J1-802PCT-US

REMARKS

Applicants hereby submit that the enclosures fulfill the requirements under 37 C.F.R. §1.821-1.825. The amendments in the specification merely insert a sequence identifier on page 84 of the specification. Given that no new sequence identifier has been added, it is believed that there is no need to provide substitute computer-readable and paper copies of the Sequence Listing. I hereby state that this submission, filed in accordance with 37 CFR §1.821(g), does not contain new matter.


Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment.

Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date:

June 21, 2001


Janis K. Fraser, Ph.D., I.D.
Reg. No. 34,819

Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110-2804
Telephone: (617) 542-5070
Facsimile: (617) 542-8906

Applicant : Takuya Tamatan, et al.
Serial No. : 09/383,551
Filed : August 26, 1999
Page : 3

Attorney's Docket : 06501-039001 / J1-802PCT-US

“Version With Markings to Show Changes Made”

In the specification:

Paragraph beginning at page 84, line 4, has been amended as follows:

After the purified "JTT-1 antigen" was subjected to SDS-PAGE, the N-terminal amino acid sequence was determined by the usual method. The result revealed that "JTT-1 antigen" contained an amino acid sequence Glu-Leu-Asn-Asp-Leu-Ala-Asn-His-Arg (amino acid residues 21-29 of SEQ ID NO:15).